Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations Academic Article uri icon


MeSH Major

  • HLA Antigens
  • Lymphocyte Depletion
  • Myelodysplastic Syndromes
  • Stem Cell Transplantation
  • T-Lymphocytes
  • Transplantation, Isogeneic


  • TP53 alterations portend extremely poor prognosis in patients with mantle cell lymphoma treated with standard treatment modalities. We reviewed outcomes of 42 patients with available TP53 status who had received a reduced-intensity or non-myeloablative allogeneic haematopoietic cell transplant at our institution. We demonstrated a 2-year overall survival and progression-free survival of 78% [95% confidence interval (CI) 60-88] and 61% (95% CI 43-75), respectively. The 2-year cumulative incidences of relapse and non-relapse mortality were 19% and 20%, respectively. Importantly, there is no significant difference among patients with and without TP53 alterations, suggesting for the first time a beneficial treatment modality for these high-risk patients.

publication date

  • March 2019



  • Academic Article



  • eng

PubMed Central ID

  • PMC6399037

Digital Object Identifier (DOI)

  • 10.1111/bjh.15721

PubMed ID

  • 30537212

Additional Document Info

start page

  • 1006

end page

  • 1010


  • 184


  • 6